GH1 Specific Neutra™ Antibody Products

Growth hormone 1 (GH1), also known as pituitary growth hormone or somatotropin, is a protein consisting of 191 amino acids encoded by the GH1 gene in humans. It plays a crucial role as a classical endocrine hormone produced primarily by the pituitary gland. GH1 binds to the growth hormone receptor (GHR), a member of the cytokine receptor superfamily, exerting various effects on physiological systems. GH1 impacts ovarian and testicular function through direct interactions with GHR and indirect effects mediated by secondary factors such as insulin-like growth factor (IGF), which is usually synthesized by the liver following GH stimulation. Beyond its pituitary expression, GH1 is also locally expressed in tissues outside the pituitary gland, where it can have autocrine and paracrine effects. Dysregulation of GH1 secretion can lead to disorders such as acromegaly, necessitating treatment strategies aimed at controlling GH release or inhibiting GHR activation.

Its Gene ID: 2688, UniProtKB ID: P01241, and OMIM ID: 139250.

Fig.1 The major actions of GH and IGF in ovarian physiology.¹

GH1 Signaling Pathway

The signaling pathway of GH1 involves its binding to GHR, leading to receptor dimerization and activation of Janus Kinase 2 (JAK2). Activated JAK2 phosphorylates tyrosine residues on the intracellular domain of GHR, facilitating the recruitment and phosphorylation of Signal Transducers and Activators of Transcription (STAT) proteins. Additionally, GH1 signaling can activate other pathways like MAPK/ERK and PI3K/AKT. GH1 stimulation triggers the liver to produce IGF, which in turn mediates numerous indirect effects of GH1. IGF acts through its receptor, the IGF-1 receptor, initiating similar signaling cascades as GH1-GHR interaction. Overall, the GH1 signaling pathway regulates growth, metabolism, and various physiological functions, impacting development, tissue repair, and homeostasis.

Fig.2 The major signaling networks of GH1 and IGF.¹

GH1 Antibodies in Therapies

Antibodies targeting GH1 have been engineered for a multitude of therapeutic applications. In cases of growth hormone deficiency (GHD), engineered GH1 antibodies mimic natural growth hormone, facilitating growth and development. Conversely, in conditions like acromegaly, these antibodies act by binding to excessive growth hormone, thus assisting in the regulation of its activity and control of the disorder. Moreover, in autoimmune disorders such as autoimmune polyendocrine syndrome type 1 (APS1), GH1 antibodies play a role in modulating the immune response and reducing harmful autoantibodies. Additionally, in cancer therapy, GH1 antibodies have the potential to target growth hormone signaling pathways, potentially impeding tumor growth.

Services

Creative Biolabs provides several neutralizing antibodies that target and bind to GH1, which can be utilized for WB and other applications to assist in your research projects. Customized services and designs for neutralizing antibodies are also available here. Please get in touch with us for more information about our GH1 antibody products.

REFERENCE

1. Ipsa, Emina, et al. "Growth hormone and insulin-like growth factor action in reproductive tissues." Frontiers in endocrinology 10 (2019): 777. Under open access license CC BY 4.0, without modification.